Publication/Presentation Date

6-30-2020

Abstract

The treatment of metastatic breast cancer has undergone significant changes in recent years. New classes of medications have been approved by the Food and Drug Administration (FDA) for use in clinical practice to extend progression-free survival and overall survival along with increasing response rate. Here, we present a case report of pneumonitis as a rare side effect of palbociclib in the treatment of metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (ERBB2-) breast cancer in addition to endocrine therapy. We also review the literature for other reports of pneumonitis during treatment with palbociclib. Through this case report and review of the literature, we aim to shed light on this rare side effect of palbociclib along with its successful management.

Volume

12

Issue

6

First Page

8929

Last Page

8929

ISSN

2168-8184

Disciplines

Medicine and Health Sciences

PubMedID

32760629

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Hematology-Medical Oncology Division Fellows and Residents, Department of Medicine Faculty, Department of Medicine Fellows and Residents, Fellows and Residents

Document Type

Article

Share

COinS